
Thursday July 23, 2015
Promising Therapy for LRBA Deficiency

NIH researchers and their colleagues from Cincinnati Children’s Hospital have shown that the drug abatacept, which is FDA-approved for treating rheumatoid arthritis, may be a promising, long-term therapy for a rare immune disorder called LRBA deficiency.

No hay comentarios:
Publicar un comentario